Literature DB >> 17460704

Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders.

W G Morice, C A Hanson, S Kumar, L A Frederick, C E Lesnick, P R Greipp.   

Abstract

Mesh：

Year:  2007        PMID： 17460704     DOI： 10.1038/sj.leu.2404712

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.

Authors:  Chiara Lobetti-Bodoni; Barbara Mantoan; Luigia Monitillo; Elisa Genuardi; Daniela Drandi; Daniela Barbero; Elisa Bernocco; Mario Boccadoro; Marco Ladetto
Journal:  Ther Adv Hematol       Date:  2013-06

2.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

3.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

4.  The current status of minimal residual disease assessment in myeloma.

Authors:  S K Kumar; S V Rajkumar
Journal:  Leukemia       Date:  2014-02       Impact factor: 11.528

Review 5.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

6.  Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.

Authors:  H Robert Bergen; Surendra Dasari; Angela Dispenzieri; John R Mills; Marina Ramirez-Alvarado; Renee C Tschumper; Diane F Jelinek; David R Barnidge; David L Murray
Journal:  Clin Chem       Date:  2015-10-01       Impact factor: 8.327

7.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

Authors:  W I Gonsalves; S V Rajkumar; V Gupta; W G Morice; M M Timm; P P Singh; A Dispenzieri; F K Buadi; M Q Lacy; P Kapoor; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

8.  Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.

Authors:  Sang-Yong Shin; Seung-Tae Lee; Hee-Jin Kim; Suk Jin Kim; Kihyun Kim; Eun Suk Kang; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

9.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

10.  Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

Authors:  A L Feldman; D X Sun; M E Law; A J Novak; A D Attygalle; E C Thorland; S R Fink; J A Vrana; B L Caron; W G Morice; E D Remstein; K L Grogg; P J Kurtin; W R Macon; A Dogan
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.